CSL Stock Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CSL from our risk checks.
My Notes
NewNotes are coming soon
CSL Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$293.00 |
52 Week High | AU$304.70 |
52 Week Low | AU$240.10 |
Beta | 0.18 |
1 Month Change | 1.82% |
3 Month Change | 3.44% |
1 Year Change | 12.54% |
3 Year Change | -5.91% |
5 Year Change | 100.08% |
Change since IPO | 36,525.37% |
Recent News & Updates
Recent updates
CSL (ASX:CSL) Seems To Use Debt Quite Sensibly
Nov 17CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate
Oct 27We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Aug 19Is CSL Limited (ASX:CSL) Trading At A 22% Discount?
Jul 29CSL's (ASX:CSL) Problems Go Beyond Weak Profit
Feb 22Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?
Jan 19With EPS Growth And More, CSL (ASX:CSL) Is Interesting
Dec 08CSL (ASX:CSL) Seems To Use Debt Quite Sensibly
Oct 26We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation
Oct 05Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching
Sep 02CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate
Jul 22CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet
Jul 01Do CSL's (ASX:CSL) Earnings Warrant Your Attention?
May 20We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Mar 29Is Weakness In CSL Limited (ASX:CSL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 08A Look At The Fair Value Of CSL Limited (ASX:CSL)
Feb 19Results: CSL Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 19Here's Why I Think CSL (ASX:CSL) Might Deserve Your Attention Today
Feb 01Announcing: CSL (ASX:CSL) Stock Increased An Energizing 152% In The Last Five Years
Jan 14Our Take On CSL's (ASX:CSL) CEO Salary
Dec 24We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Dec 06Is Weakness In CSL Limited (ASX:CSL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jul 27Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?
Jul 06Shareholder Returns
CSL | AU Biotechs | AU Market | |
---|---|---|---|
7D | -1.8% | -1.4% | 0.6% |
1Y | 12.5% | 11.8% | 3.5% |
Return vs Industry: CSL matched the Australian Biotechs industry which returned 11.8% over the past year.
Return vs Market: CSL exceeded the Australian Market which returned 3.5% over the past year.
Price Volatility
CSL volatility | |
---|---|
CSL Average Weekly Movement | 2.3% |
Biotechs Industry Average Movement | 9.1% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 15.7% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CSL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: CSL's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1916 | 30,000 | Paul Perreault | https://www.csl.com.au |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.
CSL Limited Fundamentals Summary
CSL fundamental statistics | |
---|---|
Market Cap | AU$142.11b |
Earnings (TTM) | AU$3.17b |
Revenue (TTM) | AU$14.86b |
44.5x
P/E Ratio9.5x
P/S RatioIs CSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CSL income statement (TTM) | |
---|---|
Revenue | US$10.56b |
Cost of Revenue | US$4.83b |
Gross Profit | US$5.73b |
Other Expenses | US$3.48b |
Earnings | US$2.25b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 14, 2023
Earnings per share (EPS) | 4.68 |
Gross Margin | 54.27% |
Net Profit Margin | 21.35% |
Debt/Equity Ratio | 56.7% |
How did CSL perform over the long term?
See historical performance and comparison